UTHR Projected Dividend Yield
United Therapeutics Corp ( NASDAQ : UTHR )United Therapeutics is a biotechnology company. Co. markets and sells four commercial therapies in the U.S. to treat pulmonary arterial hypertension: Tyvaso® (treprostinil) Inhalation Solution (Tyvaso), which includes the Tyvaso Inhalation System; Remodulin® (treprostinil) Injection (Remodulin); Orenitram® (treprostinil) Extended-Release Tablets; and Adcirca® (tadalafil) Tablets. Tyvaso has also been approved to treat pulmonary hypertension associated with interstitial lung disease. In the U.S., Co. also markets and sells an oncology product, Unituxin® (dinutuximab) Injection, which is approved for treatment of high-risk neuroblastoma, and the Remunity® Pump for Remodulin. 20 YEAR PERFORMANCE RESULTS |
UTHR Dividend History Detail UTHR Dividend News UTHR Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |